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Arsenic is a well-known environmental
toxin associated with an increased risk of
cancer and cardiovascular disease in
humans. This chemical is widely distrib-
uted because of its strong affinity with
pyrite and high concentration in hydrous
iron oxides (Nordstrom 2002). Natural
arsenic is disseminated within our living
environment by groundwater from wells
drilled into arsenic-rich geologic strata or
by ambient air during the process of min-
eral extraction (Thornton and Farago
1997; U.S. NRC 1999). Man-made
sources of arsenic also include uses in agri-
culture, husbandry, and medicine (U.S.
NRC 1999). However, the main route of
exposure for the general population in arse-
niasis-endemic areas of the world is
through the ingestion of arsenic-contami-
nated well water (U.S. NRC 1999; U.S.
PHS 1989), including those in Taiwan, the
India-Bangladesh border, and Latin
America (Bagla and Kaiser 1996; Bates
et al. 1992; Engel et al. 1994; Kumar
1997). The latest estimates indicate that
more than 100 million people worldwide
are exposed to groundwater contaminated
by arsenic compounds (Chen et al. 1999). 
Ingested arsenic has been associated
with the development of blackfoot disease
(BFD) subsequent to long-term exposure
(Chen et al. 1988; Tseng 1977). BFD is a
unique peripheral vascular disease endemic
in the southwestern coast of Taiwan.
Pathological studies have demonstrated
that 70% of BFD patients have histologic
lesions compatible with the changes of
arteriosclerosis obliterans and 30% with
the changes of thromboangiitis obliterans
(Yeh and How 1963). The fundamental
vascular change of BFD in both types is a
severe generalized arteriosclerosis (Yeh and
How 1963). Recent reports have also
showed that long-term arsenic exposure is
closely associated with an increased risk of
hypertension, diabetic mellitus, ischemic
heart disease, cerebral infarction, and
carotid atherosclerosis (Chen et al. 1995,
1996; Chiou et al. 1997; Tseng et al. 2000;
Wang et al. 2002). Arsenic is a seemingly
independent risk factor for multiple cardio-
vascular end points in addition to tradi-
tional risk factors such as high fat intake,
alcohol consumption, and cigarette smok-
ing. However, the pathological mechanism
by which arsenic induces changes leading
to vascular disorders remains to be delin-
eated. Response to injured endothelial cells
and/or stimulating proliferation of a single
smooth muscle cell have long been hypoth-
esized for the pathogenesis of atherosclero-
sis (Libby et al. 2002; Ross 1986, 1999).
Underlying this hypothesis, activation and
recruitment of blood leukocytes, as well as
continuing expression of proinflammatory
factors in the lesion area, characterize all
stages of atherogenesis. To date, however,
the contribution of inflammatory media-
tors has not been investigated for arsenic-
associated vascular disease in human
population. Arsenite, trivalent arsenic, is
generally considered a poor DNA-damag-
ing agent at noncytotoxic concentrations in
cell culture studies (Kitchin 2001). We
hypothesize that arsenic-associated vascular
disorders observed in the human popula-
tion may arise from alterations in the
expression of a variety of inflammatory
genes that participate in the development
of atherosclerotic lesions during long-term
exposure. 
To identify aberrant gene expression in
inflammation that is possibly involved in
arsenic atherogenicity, we used a human
cDNA microarray to search for differentially
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Long-term arsenic exposure is associated with an increased risk of vascular diseases including
ischemic heart disease, cerebrovascular disease, and carotid atherosclerosis. The pathogenic
mechanisms of arsenic atherogenicity are not completely clear. A fundamental role for inﬂamma-
tion in atherosclerosis and its complications has become appreciated recently. To investigate
molecular targets of inﬂammatory pathway possibly involved in arsenic-associated atherosclero-
sis, we conducted an exploratory study using cDNA microarray and enzyme-linked immunosor-
bent assay to identify genes with differential expression in arsenic-exposed yet apparently healthy
individuals. As an initial experiment, array hybridization was performed with mRNA isolated
from activated lymphocytes of 24 study subjects with low (0–4.32 µg/L), intermediate
(4.64–9.00 µg/L), and high (9.60–46.5 µg/L) levels of blood arsenic, with each group compris-
ing eight age-, sex-, and smoking frequency-matched individuals. A total of 708 transcripts of
known human genes were analyzed, and 62 transcripts (8.8%) showed signiﬁcant differences in
the intermediate or high-arsenic groups compared with the low-level arsenic group. Among the
signiﬁcantly altered genes, several cytokines and growth factors involving inﬂammation, includ-
ing interleukin-1 beta, interleukin-6, chemokine C-C motif ligand 2/monocyte chemotactic pro-
tein-1 (CCL2/MCP1), chemokine C-X-C motif ligand 1/growth-related oncogene alpha,
chemokine C-X-C motif ligand 2/growth-related oncongene beta, CD14 antigen, and matrix
metalloproteinase 1 (interstitial collagnase) were upregulated in persons with increased arsenic
exposure. Multivariate analyses on 64 study subjects of varying arsenic exposure levels showed
that the association of CCL2/MCP1 plasma protein level with blood arsenic remained signifi-
cant after adjustment for other risk factors of cardiovascular diseases. The results of this gene
expression study indicate that the expression of inflammatory molecules may be increased in
human subjects after prolonged exposure to arsenic, which might be a contributory factor to the
high risk of atherosclerosis in arseniasis-endemic areas in Taiwan. Further multidisciplinary
studies, including molecular epidemiologic investigations, are needed to elucidate the role of
arsenic-associated inﬂammation in the development of atherosclerosis and subsequent cardiovas-
cular disease. Key words: arsenic exposure, atherosclerosis, gene expression, inflammation.
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http://dx.doi.org/ [Online 23 July 2003]expressed genes in peripheral blood lympho-
cytes (PBLs) from arsenic-exposed individu-
als. Recent studies in microarray analysis
concerning adverse health effects of arsenic
have been focused mainly on its carcino-
genic properties (Chen et al. 2001; Lu et al.
2001; Yih et al. 2002). Few gene expression
studies have focused on the atherogenic
effect of arsenic exposure. In this report, we
ﬁrst demonstrate the application of cDNA
microarray technology to identify gene
expression changes in PBLs from arsenic-
exposed individuals and show that blood
arsenic is significantly associated with
changes in transcription levels of several
inﬂammatory mediator genes that have been
implicated in the atherosclerotic process.
PBLs do not represent all the cells involved
in progression of atheroma formation but
are the only collectable cell samples from
apparently healthy humans in a population
study, which may reﬂect the inﬂammatory
response to an environmental injury. The
enhanced expression of inﬂammatory mole-
cules in blood leukocytes from an arsenic-
exposed population may contribute to the
development of atherosclerosis associated
with arsenic exposure.
Materials and Methods
Study Subjects and Tissue Samples
Sixty-four residents identiﬁed as consumers
of arsenic-tainted well water in Lanyang
Basin of northeastern Taiwan, Republic of
China, were recruited for previous studies of
arsenic toxicity (Wu et al. 2001). For the
present study, frozen peripheral blood lym-
phocytes and plasma samples previously
stored from the study subjects were analyzed.
Detailed characteristics of the study area,
subject recruitment and blood collection,
and determination of arsenic concentration
in whole blood samples have been described
previously (Wu et al. 2001). Isolation, freez-
ing, and storage of the lymphocytes in liquid
nitrogen were performed according to the
methods described by Venkataraman and
Westerman (Venkataraman and Westerman
1986). Plasma samples were preserved at
–20°C until protein assay was performed
for this study. Computerized records of the
serum levels of total cholesterol and triglyc-
erides initially determined by an autoana-
lyzer were retrieved for the study subjects.
Information on demographic or clinical
characteristics, as well as lifestyle data
including alcohol consumption and smok-
ing habits of the study subjects were also
obtained from previous records. All study
subjects gave their consent and were free of
clinical symptoms,as described in our
previous study using the same population
(Wu et al. 2001).
mRNA Preparation and cDNA
Microarray Analysis
Because of limited samples of frozen
lymphocytes, only the study subjects who
had a cell number of 15–20 × 106 in stock
were selected for the cDNA microarray
hybridization analysis as an initial experi-
ment. A total of 24 study subjects whose
cells were available from the archives were
further separated into groups on the basis
of blood arsenic levels [low (0.00–4.32
µg/L), intermediate (4.64–9.00 µg/L) and
high (9.60–46.5 µg/L)], with each group
comprising eight similar age-, sex-, and
smoking-frequency–matched individuals.
Lymphocyte samples were thawed and cul-
tured in RPMI-1640 medium (GIBCO,
Grand Island, NY, USA) supplemented
with 20% heat-inactivated fetal bovine
serum (Hyclone Laboratory, Logan, UT,
USA), 100 U/mL penicillin, and 100
µg/mL streptomycin at 37°C in a humidi-
ﬁed atmosphere containing 5% CO2 for 68
hr. Using TRI reagent (Molecular Research
Center, Cincinnati, OH, USA), we
extracted a total of 30–50 µg cellular RNA
from the harvested cells for each study sub-
ject, which was further pooled into groups
of low, intermediate, or high arsenic levels
for subsequent isolation of mRNA. mRNA
was extracted using Oligotex-dT resin
(Qiagen, Hilden, Germany) and was used
to prepare targets for cDNA microarray
hybridization and first-strand cDNA for
quantitative real-time polymerase chain
reaction (PCR) assay. 
Seven hundred eight cDNA elements
used as probes, including 662 known genes
of potential signiﬁcance in arsenic toxicity,
16 housekeeping genes, and 22 expressed-
sequence tags (ESTs), were prepared by
PCR ampliﬁcation of IMAGE consortium
cDNA clones and arrayed on a 5 × 8 mm
nylon membrane, using methods described
previously (Chen et al. 1998). Also
included in the membrane chip were eight
plant genes, whose hybridization results
served as negative controls. The cDNA
microarray hybridization experiment was
performed with this 708 cDNA probes
array using a colorimetric detection
method described previously (Yih et al.
2002). Brieﬂy, biotin-labeled cDNA targets
were prepared from 2 µg mRNA by reverse
transcriptase (Superscript II; GIBCO BRL,
Gaithersburg, MD, USA) incorporation of
biotin-16–2'-deoxyuridine-5'-triphosphate
(Roche Diagnostic, Mannheim, Germany).
After precipitation, the labeled targets were
dissolved in hybridization buffer and incu-
bated with the prehybridization-treated
probes array at 65°C overnight. The
hybridized arrays were then washed at
room temperature twice in 2 × SSC
(0.15 M NaCl/0.015 M Na citrate, pH
7.0), 0.1% sodium dodecyl sulfate (SDS)
for 5 min, and 3 times at 65°C in 0.1 ×
SSC, 0.1% SDS for 15 min. After thor-
ough washing, the arrays were blocked and
incubated with streptavidin-β-galactosidase
conjugate reagent for chromagen develop-
ment. After a wash to remove any unbound
conjugates, an X-gal substrate solution was
added to the array and incubated at 37°C
for 30 min with occasional shaking. Color
development was terminated by addition of
phosphate-buffered saline. The signal
intensity of spots on arrays was acquired
using a ﬂatbet scanner at appropriate opti-
cal resolution. Quantitative results were
analyzed using GenePix Pro (version 3.0;
Axon Instruments, Union, CA, USA) and
Microsoft Excel 2000 software (version 9;
Microsoft Corp., Taipei, Taiwan).
To allow for better comparison
between hybridization experiments, a
series of four array probes was prepared for
each membrane using known concentra-
tions of 10-fold serial dilutions of glycer-
aldehyde-3-phosphate dehydrogenase
(GAPDH) clone. A standard curve plotting
the signal intensity versus the concentra-
tion of four serial-diluted GAPDH clones
was generated for each set of gene spots to
be tested on one array. By comparing the
signal intensity of the tested spot to this
standard curve, the relative intensity of the
spot was normalized against GAPDH
intensity. After standardization, ratios of
relative intensity were calculated between
arsenic groups for all gene spots. Gene-
specific signal ratio was considered signifi-
cant if the logarithm of the ratio differed
by ≥ 3 SD from the mean log2 of the ratio
for the housekeeping genes set. To date,
arsenic has not been shown to have appre-
ciable effects on the expression of these
housekeeping genes.
Quantitative Reverse-Transcriptase–
Polymerase Chain Reaction Analysis
The quantitation of mRNA level was
carried out using a real-time SYBER Green I
fluorescence detection method as described
previously (Morrison et al. 1998; Wittwer
et al. 1997). In brief, 1 µg mRNA was ﬁrst
reverse-transcribed into cDNA using ran-
dom primers (Roche Diagnostic) and puri-
fied by a 30-min incubation at 37°C with
RNase H (Invitrogen, Carlsbad, CA, USA)
followed by ethanol precipitation. The spe-
cific cDNA of interest and a reference
cDNA, GAPDH, were PCR-ampliﬁed sep-
arately in optical tubes and caps using the
ABI PRISM 7700 sequence detection sys-
tem (Applied Biosystems, Foster, CA,
USA). Primer design and PCR reaction
were performed according to commercial
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Dissociation curve analysis was performed
after PCR amplification (ABI PRISM
7700; Applied Biosystems) to ensure no
fluorescence contamination from nonspe-
ciﬁc dsDNA product. Results of the deriva-
tive dissociation curve proﬁle exhibited no
nonspeciﬁc products in PCR reaction solu-
tion. All PCR reactions were performed
in duplicate.
Initial template concentration of a
specific gene was derived from the cycle
number at which the fluorescent signal
crossed a threshold in the exponential
phase of the PCR reaction. For comparison
of mRNA levels between groups, relative
gene expression level was first determined
by subtracting from the respective cycle
number of GAPDH gene for each group.
Values were then used to calculate for
relative folds normalized to the relative
amounts of the same gene in the low-level
arsenic group.
Enzyme-linked immunosorbent assay.
Selected inflammatory molecules, includ-
ing interleukin-1 beta (IL1β), interleukin-6
(IL6), chemokine C-C motif ligand
2/monocyte chemotactic protein-1
(CCL2/MCP1), and chemokine C-X-C
motif ligand 1/growth-related oncogene
alpha (CXCL1/GRO1) protein levels in
plasma, were measured for the 64 study
subjects by enzyme-linked immunosorbent
assay (ELISA; Biotrak, Piscataway, NJ,
USA) according to the manufacturer’s
instructions. Lower limits of detection of
assays for IL1β, IL6, CCL2/MCP1, and
CXCL1/GRO1 were 0.31, 0.31, 20.5, and
15.6 pg/mL, respectively. 
Statistical Methods
For comparison of more than two groups,
one-way analysis of variance (ANOVA) or
chi-square test was applied where appropri-
ate. Spearman correlation coefficient was
used to determine statistical association
between study variables. We performed
multiple linear regression analysis to exam-
ine the effect of arsenic concentration on
the protein expression level in plasma after
controlling for confounding factors.
Statistical significance was accepted at a
level of p < 0.05.
Results
Differentially Expressed Genes in
Lymphocytes of Arsenic-Exposed
Individuals
To identify genes potentially associated with
arsenic atherogenicity, we compared the
gene expression proﬁle of peripheral blood
lymphocytes from 24 selected individuals of
low-, intermediate-, or high-level arsenic
exposure groups (Figure 1; detailed informa-
tion on the 708 cDNA clones spotted on
membrane chip, as well as the resultant sig-
nal intensity for each study gene, are accessi-
ble at http://www.ibms.sinica.edu.tw/
~bmtcl/As-chip-TCL01-PBL.xls).
Hybridization intensities of the four serially
diluted GAPDH clones are shown on the
eighth line from the top. The GAPDH tran-
scription levels showed a logarithmic rela-
tion with signal intensity, and a standard
curve for linear transformation was gen-
erated as described in ‘Materials and
Methods.” Table 1 includes the relative
intensities of nine housekeeping genes
among groups of varying arsenic exposure;
the other seven housekeeping genes were
either duplicates or had an expression level
Toxicogenomics | Inflammatory molecules and arsenic exposure
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Low-level arsenic group Intermediate-level arsenic group
Deposited GAPDH clones,
1:1000, 1:100, 1:10, 1:1
dilution, from left to right.
High-level arsenic group
Figure 1. Section of colorimetric cDNA microarray hybridized to mRNA extracted from peripheral blood
lymphocytes of various arsenic-exposed groups. mRNA was extracted from pooled total RNA samples
obtained from eight individuals representative of each arsenic group. The eight individuals were age, sex,
and smoking frequency-matched among groups. The array contained 708 cDNA elements, each repre-
senting an individual gene. One membrane is shown for each arsenic group. The serial-diluted GAPDH
spots in one membrane, as shown in the box, were used to calibrate the relative intensity for each indi-
vidual image in the same membrane.
Table 1. Relative intensity of mRNA levels of nine housekeeping genes in peripheral blood lymphocytes from arsenic-exposed study subjects, Lanyang Basin,
Taiwan.a,b
Arsenic concentration in blood (µg/L)
Low Intermediate High log2 log2 log2
Accession numberc Descriptionc (0.00–4.32) (4.64–9.00) (9.60–46.5) (Intermediate/low) (High/low) (High/intermediate)
AA186639 Ribosomal protein S27 1313.14  1414.26  1085.65  0.107  –0.274  –0.381 
AA126291 H3 histone, family 3B  1314.83  1103.04  1204.01  –0.253  –0.127  0.126 
AA053244  Basic transcription factor 3  152.35  85.07  106.88  –0.841  –0.511  0.329 
AA065001 Ribosomal protein S3  1510.32  1327.67  1172.98  –0.186  –0.365  –0.179 
AA147674 Ribosomal protein S20 936.38  921.45  890.70  –0.023  –0.072  –0.049 
AA064618 Ribosomal protein L28 204.48  246.29  161.65  0.268  –0.339  –0.607 
AA131097 Ribosomal protein S5  407.75  320.50  426.96  –0.347  –0.066  0.414 
M33197 GAPDH, 1:10 dilution 155.35  148.98  174.85  –0.060  0.171  0.231 
H66115 Glucose phosphate isomerase 693.60  533.72  624.58  –0.378  –0.151  0.227 
amRNA was extracted from pooled total RNA samples obtained from 8 individuals representative of each arsenic group. The eight individuals were age-, sex,- and smoking-frequency–
matched among groups. bQuantiﬁcation of each individual gene in one group was standardized to a calibration curve established from serial dilutions of GAPDH gene of the same group.
cInformation from the UniGene database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene). dThe means of the logarithm base 2 of signal ratio (± SD) for the housekeeping
genes were –0.190 (± 0.322), –0.178 (± 0.217), and 0.012 (± 0.344) for intermediate versus low, high versus low, and high versus intermediate, respectively.below threshold. As demonstrated in
Table 1, housekeeping genes showed
relatively constant expression levels among
groups; the means of the logarithm base 2 of
signal ratio (± SD) were –0.190 (± 0.322),
–0.178 (± 0.217), and 0.012 (± 0.344) for
intermediate versus low, high versus low,
and high versus intermediate, respectively.
On the basis of the expression variation with
3 × SD from the mean log for the house-
keeping genes, we identified 26 cDNA
clones with an increased expression signal in
intermediate- or high-level arsenic groups,
and 36 cDNA clones with reduced expres-
sion in intermediate- or high-level arsenic
groups compared with the low-level arsenic
group. Except for five clones of EST or
clones withdrawn from the Unigene data-
base (http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db=unigene), the remaining 57
genes of known function included those
involving growth factor or cytokine related,
signaling transduction pathway, tran-
scription regulatory components, cell-cycle
control, DNA replication/repair activity,
redox homeostasis, and matrix-degrading
enzymes (Table 2). 
Of particular interest, genes of
cytokine-related or growth factors involv-
ing inflammation were significantly ele-
vated in the high-level arsenic exposure
groups (Table 2). These inﬂammatory mol-
ecules have recently been implicated in the
atherosclerotic process for a variety of vas-
cular diseases. A number of these genes
detected by the microarray as significantly
induced in lymphocytes, such as IL1β, IL6,
CCL2/MCP1, CXCL1/GRO1, chemokine
C-X-C motif ligand 2/growth-related
oncogene beta (CXCL2/GRO2), CD14
antigen (CD14), and interstitial collagenase
matrix metalloproteinase 1 (MMP1), were
selected for a conﬁrmation test using a real-
time reverse-transcriptase–polymerase chain
reaction method. As indicated in Figure 2,
we reconfirmed the change profile in gene
expression of these genes in parallel with
the arsenic exposure group. Comparison of
the colorimetric cDNA microarray method
with SYBR Green I real-time PCR assay
(Applied Biosystems) showed consistent
fold changes in expression for these six
genes.
Protein Levels of Inﬂammatory
Molecules in Plasma of Arsenic-
Exposed Individuals
Four genes detected by the microarray as
signiﬁcantly induced in PBL of the higher-
level arsenic groups, including IL1β, IL6,
CCL2/MCP1, and CXCL1/GRO1, were
studied by ELISA assay to quantitatively
evaluate protein expression level in plasma
samples of 64 study subjects. Demographic
and clinical characteristics of the study sub-
jects by blood arsenic concentration are
summarized in Table 3. As shown in this
table, the three groups of varying arsenic
exposure did not differ with respect to age,
percentage of male gender, current smoker,
serum cholesterol, or triglyceride but dif-
fered in regard to body mass index. Study
subjects of high-level arsenic group were
signiﬁcantly underweight as compared with
the other two groups (p = 0.021). 
Table 4 shows the results of ELISA
assay for IL1β, IL6, CCL2/MCP1, and
CXCL1/GRO1 protein expression level in
plasma of the study subjects. Although
there was considerable variation within
each arsenic group, a positive correlation
was observed between arsenic exposures
and plasma protein levels of CCL2/MCP1.
Because the distribution of plasma protein
levels in these study subjects was wide and
skewed to the left, individual measure-
ments of protein level were logarithmically
transformed in the next regression analysis
for CCL2/MCP1 to reduce the influence
of extreme values on the estimates of para-
meters. As summarized in Table 5, we
found no significant association of plasma
CCL2/MCP1 protein level with body mass
index, cholesterol, triglyceride, or smoking
status. However, blood arsenic concentra-
tion was significantly associated with the
CCL2/MCP1 protein level after adjust-
ment for age and gender through multi-
variate regression analysis.
Discussion
Arsenic is an environmental contaminant
that warrants high concern for human
health. Long-term arsenic exposure is
closely associated with adverse health
effects, including several vascular disorders
(Chen et al. 1996; Chiou et al. 1997; Engel
et al. 1994; Tseng et al. 1995, 1996; Wang
et al. 2002). The possibility that arsenic
induces atherosclerosis through its actions
on the change of inflammatory-related
gene expression needs to be elucidated. By
using cDNA microarray analysis on circu-
lating lymphocytes from healthy arsenic-
exposed individuals, we found that
alteration in expression level of several
genes involved in inflammation showed a
positive correlation with arsenic concentra-
tion in the whole blood of study subjects.
In some of study genes, a dose–response
relationship between transcription level
and arsenic exposure was not observed; in
this case, there might be other risk factors
interfering with gene expression, thus con-
founding the dose-dependent pattern
under study in this population. As individ-
ual RNA samples were not available, the
inﬂuence of a potential confounding effect
was not examined. However, further
studies of plasma protein level by ELISA
exhibited a significant correlation with
CCL2/MCP1 that remained significant
after adjustment for other risk factors of
cardiovascular disease. In contrast, we
found no significant correlation of plasma
protein levels for IL1β, IL6, and CXCL1/
GRO1 with blood arsenic as observed in
the gene expression studies. It is probable
that because of posttranscriptional regula-
tion, changes in mRNA expression would
not show corresponding changes in protein
levels. In addition, the number of study
subjects for these genes may not be large
enough to draw a definite conclusion on
the association between plasma protein
level and arsenic exposure gradient. Taken
together, the enhanced expression of the
inﬂammatory molecules observed in blood
lymphocytes of arsenic-exposed study sub-
jects may contribute to the atherosclerotic
process caused by arsenic, although other
gene factors cannot be excluded. 
The role of inflammatory cytokines or
growth factors with inﬂammatory reactivity
has gained increasing attention in the
pathogenesis of atherosclerotic lesions
(Libby et al. 2002; Ross 1999). The main
contributors to the risk for atherosclerosis
include lipoprotein, homocysteine, hyper-
tension, diabetes, infectious agents, and
oxidant stress (Libby et al. 2002). Arsenic
is widely accepted as a prooxidant stimulus.
In humans, prolonged exposure to arsenic
that accompanies persistent oxidative stress
in the vasculature system might trigger
inflammation and thereafter lead to
atheroma formation. Although directed
migration of mononuclear leukocytes,
including T lymphocytes, into the tunica
intima by chemokines produced by
endothelial and smooth muscle cells char-
acterizes the initiation of the artheroscle-
rotic lesions, the activated leukocytes in
arterial intima also secrete proinﬂammatory
cytokines that amplify inflammatory
response in the lesion (Libby 2002). How
the induction of inflammatory mediators
in activated T lymphocytes residing in
blood circulation or in arterial intima of
arsenic-exposed humans might lead to ath-
erosclerosis requires further study. In the
present study, gene expression of IL1β and
IL6 was elevated in association with arsenic
exposure in the study subjects. IL1β con-
tributes to vascular smooth muscle cell
(VSMC) proliferation and lesion progres-
sion in atherosclerosis (Nathe et al. 2002).
IL6 plays a role in atherosclerosis as a medi-
ator in chemotactic activity or in cell prolif-
eration after stressful stimuli (Klouche et al.
2000; Verma et al. 2002). CCL2/MCP1 is a
key mediator of leukocyte transmigration
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Table 2. Relative intensity of mRNA levels of differentially expressed genes in peripheral blood lymphocytes from arsenic-exposed study subjects, Lanyang Basin,
Taiwan.a,b 
Arsenic concentration in blood (µg/L)
Low Intermediate High log2 log2 log2
Accession numberc Description; symbolc (0.00–4.32) (4.64–9.00) (9.60–46.5) (Intermediate/low) (High/low) (High/intermediate)
Growth factor or cytokine-related genes
AA150507 Interleukin-1, beta; IL1β 65.12 86.88  137.87  0.416  1.082d 0.666 
N98591 Interleukin-6 (interferon, beta 2); IL6 50.95 48.54  131.15 –0.070  1.364d 1.434d
H96871 Chemokine (C-C motif) ligand 2; CCL2 36.09 113.89 105.92  1.658d 1.553d –0.105 
W42723 Chemokine (C-X-C motif) ligand 1; CXCL1 19.43 22.22 56.43  0.194  1.538d 1.344d
AA487453 Chemokine (C-X-C motif) ligand 2; CXCL2 80.61 85.57  202.63  0.086  1.330d 1.244d
R94179 Hepatoma-derived growth factor 76.53  63.92  115.21  –0.260  0.590d 0.850 
(high-mobility group protein 1-like); HDGF
H11719 CD14 antigen; CD14 6.76 9.70  14.48 0.522 1.100d 0.577 
H57126 Colony-stimulating factor 1 receptor, formerly  3.29 3.80 4.83  0.207 0.553d 0.346 
McDonough feline sarcoma viral (v-fms) 
oncogene homolog; CSF1R
H87426 Interferon gamma receptor 1; IFNGR1 114.37 47.00 75.19 –1.283e –0.605 0.678 
R45384 Activin A receptor, type 1; ACVR1 46.86 18.22 31.19 –1.363e –0.587 0.776 
R39862 Activated leukocyte cell adhesion 28.74  11.96  17.80  –1.265e –0.691 0.574
molecule; ALCAM
Signal transduction pathway genes
H11455 RAB5A, member RAS oncogene family;  81.97  34.13  50.71  –1.264e –0.693 0.571
RAB5A
R20666 Endothelial differentiation, sphingolipid  208.10  92.21  134.84  –1.174e –0.626 0.548 
G-protein-coupled receptor, 1; EDG1
R43007 Annexin A7; ANXA7 336.47 246.85 183.48  –0.447  –0.875e –0.428 
R84980 Inositol 1,3,4-triphosphate 5/6 kinase;  22.22 22.92 34.76  0.045  0.646d 0.601 
ITPK1
N62226  Phosphatidylinositol 4-kinase, catalytic,  42.87 46.04 74.82  0.103  0.804d 0.701
alpha polypeptide; PIK4CA
R39925 Phosphoinositide-3-kinase, regulatory 35.74  18.15  17.53  –0.978  –1.027e –0.049
subunit, polypeptide 1 (p85 alpha); PIK3R1
R42845 Myotubular myopathy 1; MTM1 19.61 9.95  10.39  –0.979  –0.916e 0.064 
H07920 Mitogen-activated protein kinase kinase 6 11.58  7.49  4.69  –0.630  –1.304e –0.674
T89100 Mitogen-activated protein kinase  196.18  62.01  88.79  –1.662e –1.144e 0.518 
6; MAPK6
T57875 Protein kinase C, iota; PRKCI 58.04 24.14 42.34 –1.266e –0.455 0.811 
R43147 Protein kinase, cAMP-dependent, 
regulatory, type1, alpha (tissue-speciﬁc  357.84  156.01  187.91  –1.198e –0.929e 0.268
extinguisher 1); PRKAR1A
AA018676 Protein kinase, AMP-activated, gamma 1  260.15  152.28  142.57  –0.773  –0.868e –0.095 
noncatalytic subunit; PRKAG1
Transcription regulatory genes
R08560 Spleen focus forming virus (SFFV) proviral 27.18 32.21 40.65 0.245 0.581d 0.336
integration oncogene spi1; SPI1
R15253 V-fos FBJ murine osteosarcoma viral  136.24 126.03 63.85 –0.112 –1.093e –0.981
oncogene homolog; FOS 
H24055 Heat-shock transcription factor 2; HSF2 575.88 357.86 301.82  –0.686  –0.932e –0.246 
H07034 B-cell CLL/lymphoma 6 (zinc ﬁnger 20.58  10.42  10.06  –0.983  –1.033e –0.050 
protein 51); BCL6
R39273 MAD, mothers against decapentaplegic  94.47  38.76  59.69  –1.285e –0.662 0.623 
homolog 4 (Drosophila); MADH4
H18451 Transcription factor A, mitochondrial; TFAM 100.56 41.70 56.65 –1.270e –0.828 0.442 
H09636 DEK oncogene (DNA binding); DEK 59.54 30.49 30.07 –0.965 –0.986e –0.020 
H23978 General transcription factor IIB; GTF2B 137.75 72.43 69.72 –0.927 –0.982e –0.055 
R91548 Topoisomerase (DNA) I; TOP1 194.36 85.65  159.14 –1.182e –0.288 0.894 
T65211 SFRS protein kinase 2; SRPK2 50.82 19.55 27.73 –1.378e –0.874e 0.504 
R55052 PRP4 pre-mRNA processing factor 4  156.81  89.06  84.36  –0.816  –0.894e –0.078 
homolog B (yeast); PRPF4B 
Cell-cycle control genes
N21348 Menage a trois 1 (CAK assembly factor); 3.29  2.90  6.16  –0.185  0.903d 1.088d
MNAT1
AA164211 Cyclin C; CCNC 219.44 91.80  150.92 –1.257e –0.540 0.717 
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Table 2. Continued.
Arsenic concentration in blood (µg/L)
Low Intermediate High log2 log2 log2
Accession numberc Description; symbolc (0.00–4.32) (4.64–9.00) (9.60–46.5) (Intermediate/low) (High/low) (High/intermediate)
DNA replication/repair genes
AA028094 Polymerase (DNA directed), delta 2,  144.11  141.44  229.63  –0.027  0.672d 0.699 
regulatory subunit 50kDa; POLD2
H14431 Polymerase (DNA directed), beta; POLB 32.88 16.48 18.06 –0.997 –0.864e 0.132 
AA035596 Excision repair cross-complementing 34.26  22.21  49.96  –0.625  0.544d 1.170d
rodent repair deﬁciency,
complementation group 1 (includes
overlapping antisense sequence); ERCC1
AA013051 Topoisomerase (DNA) II binding protein;  193.73  78.51  142.76  –1.303e –0.440 0.863 
TOPBP1
Redox homeostasis genes
R81700 Glutathione peroxidase 4 (phospholipid  24.12  16.35  34.27  –0.561  0.507d 1.068d
hydroperoxidase); GPX4
NM_002133 Heme oxygenase (decycling) 1; HMOX1 19.83 27.96 39.38  0.496  0.990d 0.494 
R45064 Serine/threonine kinase 38; STK38 70.88 30.52 43.83 –1.216e –0.693 0.522 
T77613 Aldehyde dehydrogenase 3 family,  23.39  10.83  12.83  –1.111  –0.866e 0.244 
member A2; ALDH3A2
R49679 COX11 homolog, cytochrome c oxidase 23.79  14.02  11.75  –0.763  –1.018e –0.255 
assembly protein (yeast); COX11
Matrix-degrading enzyme genes 
AA081006 Matrix metalloproteinase 1 (interstitial 3.29  3.68  6.47  0.161  0.973d 0.812 
collagenase); MMP1
R63637 Matrix metalloproteinase 12 4.37  5.65  6.14  0.371  0.490d 0.119 
(macrophage elastase); MMP12
N33214 Matrix metalloproteinase 14 8.91  12.10  18.38  0.442  1.044d 0.603 
(membrane-inserted); MMP14
R55625 Matrix metalloproteinase 19; MMP19 3.29 3.65 4.74 0.150 0.525d 0.375 
Miscellaneous genes 
AA134959 Interferon-induced protein with  25.97  28.95  37.84  0.157  0.543d 0.386 
tetratricopeptide repeats 4; IFIT4 
R32850 Major histocompatibility complex, class I,  13.74  13.08  20.42  -0.071  0.572d 0.643 
E; HLA-E
AA031807 Feline sarcoma oncogene; FES 9.40 6.98  14.28  –0.430 0.602d 1.032 
AA031530 Brain protein I3; BRI3 3.64 3.53 5.28  –0.044 0.537d 0.581 
R94976 PTD009 protein; PTD009 4.06 3.35 5.85  –0.275 0.529d 0.804 
AA515390  Lamin B receptor; LBR 208.98 88.26  172.33 –1.244e –0.278 0.965 
R41478 COP9 homolog; COP9 75.55 40.58 41.11 –0.897 –0.878e 0.018 
H15248 Lipase A, lysosomal acid, cholesterol  113.71  54.16  41.92  –1.070  –1.439e –0.369 
esterase (Wolman disease); LIPA
amRNA was extracted from pooled total RNA samples obtained from eight individuals representative of each arsenic group. The eight individuals were age-, sex,- and smoking-
frequency–matched among groups. bQuantiﬁcation of each individual gene in one group was standardized to a calibration curve established from serial dilutions of GAPDH gene of the
same group. cInformation from the UniGene database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene). dSigniﬁcantly upregulated, deﬁned as the log2 of signal ratio (inter-
mediate- to low- level arsenic group, high- to low-level arsenic group, or high to intermediate-level arsenic group) differs by ≥ 3 SD from the corresponding mean log2 of the ratio for the
nine housekeeping genes shown in the table. eSigniﬁcantly downregulated, deﬁned as the log2 of signal ratio (intermediate to low-level arsenic group, high- to low-level arsenic group,
or high- to intermediate-level arsenic group) differs by ≤ 3 SD from the corresponding mean log2 of the ratio for the nine housekeeping genes as shown in the table. 
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Figure 2. Relative abundance of mRNA level of IL1β, IL6, CCL2/MCP1, CXCL1/GRO1, CXCL2/GRO2, CD14, and MMP1 in peripheral blood lymphocytes of study sub-
jects by arsenic exposure group. mRNA was extracted from pooled total RNA samples obtained from eight individuals representative of each arsenic group. The
eight individuals were age, sex, and smoking frequency-matched among groups. (A) Genes obtained using a colorimetric cDNA microarray method. (B) Genes
obtained by SYBR Green I real-time PCR assay. Sequences of primers used for PCR analysis were as follows. IL1β: (F)-AGCAGAAAACATGCCCGTCTT, 
(R)-CCACATTCAGCACAGGACTCTCT. IL6: (F)-TGGCTGCAGGACATGACAA, (R)-TGAGGTGCCCATGCTACATTT. CCL2/MCP1: (F)-CCCAAGAATCTGCAGCTAACTTATT,
(R)-AAGGCATAATGTTTCACATCAACAA. CXCL1/GRO1: (F)-TTTCTGAGGAGCCTGCAACA, (R)-ATTCCCCTGCCTTCACAATG. CXCL2/GRO2: (F)-AGAGGCTGAGGAATC-
CAAGAAA, (R)-TGAGAAATGTTGACCACACACTGT. CD14: (F)-AAGGACTGCCAGCCAAGCT, (R)-TTCCCGTCCAGTGTCAGGTT. MMP1: (F)- GCAGCTTCAGTGACAAA-
CATATCC, (R)- GGTGACACCAGTGACTGCACAT. GAPDH: (F)-GGAGTCCCTGCCACACTCA, (R)-GCCCCTCCCCTCTTCAAG.to sites of inflammation and thus plays an
important role in the development of
artherosclerosis (Rosenfeld 2002).
Enhanced CCL2/MCP1 transcription level
was also detected in lymphocytes from high
arsenic level group in this study. Growth-
stimulating gene expression, such as
CXCL1/GRO1 and CXCL2/GRO2, was
upregulated in the high-level arsenic expo-
sure group. In experimental animals,
CXCL1/GRO1 protein also triggers mono-
cyte arrest on early atherosclerotic endothe-
lium (Huo et al. 2001). CXCL2/GRO2 is a
potent chemotactic agent for polymor-
phonuclear leukocytes as well (Wolpe et al.
1989). Hepatoma-derived growth factor
(HDGF) was activated in study subjects of
the high-level arsenic exposure group.
Recent studies provide evidence for HDGF
stimulation of DNA synthesis in VSMCs
(Everett et al. 2001). CD14 molecules
interact with apoptotic cells, triggering
phagocytosis of the cells and also acting as
a receptor that binds bacterial lipopolysac-
charide, triggering inflammatory responses
(Devitt et al. 1998). Colony-stimulating
factor 1 receptor (CSF1R) encodes the
receptor for macrophage colony-stimulat-
ing factor, potentially involved in promot-
ing transforming activity (Hampe et al.
1989). Enhanced gene expression of both
these genes was observed in subjects from
the high-level arsenic exposure group in the
present study. In contrast, mRNA levels of
interferon gamma receptor 1 (IFNGR1),
activin A receptor, type 1 (ACVR1), and
activated leukocyte cell adhesion molecule
(ALCAM) all exhibited downregulation in
study subjects of the high-level arsenic
exposure group. Repression of IFNGR1
was unexpected, as major histocompatibil-
ity complex, class I, E (HLA-E) was acti-
vated in association with high arsenic levels
in the study subjects. Enhanced expression
of both immune-related genes should have
increased the overall inflammatory
response. Downregulation of ACVR1 for
activin may result in loss of induction for
smooth muscle cell differentiation, and
thus is involved in plaque destabilization
(Engelse et al. 1999). ALCAM is a CD6
ligand expressed by activated leukocytes
and involved in dynamic growth and/or
migration (Swart 2002). 
Aberrant expression of inflammatory
cytokines or growth factors has been con-
sistently noted in both in vitro or in vivo
arsenic studies, although patterns of pro-
duction vary between cell systems (Chen et
al. 2001; Germolec et al. 1997, 1998; Lu et
al. 2001; Yih et al. 2002). In cultured
human keratinocytes or the Tg.Ac trans-
genic mice model, sodium arsenite induced
a dose-dependent increase in the expression
of growth factors, including granulocyte-
macrophage colony-stimulating factor,
tumor necrosis factor-alpha, or tumor
growth factor-alpha, but not in the expres-
sion of inflammatory cytokines such as
IL1β, IL6, or CCL2/MCP1 (Germolec et
al. 1997, 1998). Altered expression in these
growth factors is associated with the devel-
opment of skin neoplasia (Germolec et al.
1997, 1998). Expression of IL6, CCL2/
MCP1, CXCL1/GRO1, and CXCL2/GRO2
is decreased in human ﬁbroblast cells after
treatment with 5 µM arsenite for 0–24 hr
(Yih et al. 2002). Results of another study,
however, showed an enhanced expression
of inflammatory cytokines or cytokine-
related components, such as IL1 receptor
and IL6 receptor, in arsenic-transformed
cells associated with malignant transforma-
tion (Chen et al. 2001). In arsenic-exposed
human livers, expression of hepatocyte
growth factors IL1β, and IL6 receptor is
also increased (Lu et al. 2001). In our
study, increased gene expression of IL1β,
IL6, CCL2/MCP1, CXCL1/GRO1, CXCL2/
GRO2, and HDGF as detected by cDNA
microarray was observed in association
with blood arsenic in activated lympho-
cytes of study subjects who had ingested
arsenic-tainted well water for an extended
period of time. The speciﬁc proﬁle change
of inﬂammatory molecules in leukocytes of
the vasculature system identified in this
study may differ from that found in previ-
ous studies using different cell systems;
these studies usually focused on tumor
development or high-dose treatments of
arsenite. Recently, in cultured VSMCs we
also found elevated expression of IL6 and
CCL2/MCP1 genes in a dose-dependent
manner after 0–5 µM arsenite treatment
(Lee PC and Lee TC. Unpublished data).
Atherosclerotic lesions have shown prolifer-
ation of smooth muscle cells involving acti-
vation and proliferation of macrophages
and T lymphocytes, cytokine production,
and oxidized low-density lipoprotein accu-
mulation (Ross 1999). Studies have indi-
cated that cholesterol and lipid uptake are
unimportant factors for ischemic heart dis-
ease or peripheral vascular disease in arseni-
asis-hyperendemic areas in Taiwan (Chen
et al. 1996; Hsueh et al. 1998; Tseng et al.
1997). Arsenic-induced inﬂammatory reac-
tion has a potential contribution to the
artherogenic effect of arsenic, possibly
derived from a coordinated involvement of
leukocyte recruitment and smooth muscle
cell proliferation.
Alteration of gene expression involving
signal transduction pathways or transcrip-
tion regulatory components related to
arsenic exposure was also observed in this
study. Most of these genes were repressed
in study subjects of the high-level arsenic
Toxicogenomics | Inflammatory molecules and arsenic exposure
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Table 3. Demographic and clinical characteristics of the study subjects as determined by arsenic con-
centration in whole blood samples, Lanyang Basin, Taiwan.a
Arsenic concentration in blood (µg/L)
Low Intermediate High
Characteristics (0.00–4.32) (4.64–9.00) (9.60–46.5)
Total subjects  21 22 21
Age (years) 56.4 ± 6.7 58.7 ± 6.7 56.5 ± 9.4
Gender (% male) 33.3 54.6 33.3
Body mass index (kg/m2)* 25.8 ± 3.8 25.4 ± 3.8 22.9 ± 3.2
Current smoker (%) 23.8 36.4 33.3
Serum cholesterol (mmol/L) 207.3 ± 33.4 219.0 ± 31.9 203.7 ± 37.8
Serum triglyceride (mmol/L) 135.2 ± 108.7 144.7 ± 87.3 117.0 ± 59.3
aValues are shown as means ± SD for continuous variables and percentages for dichotomous variables. *p < 0.05,
derived from an ANOVA F test for the hypothesis that there was no difference among groups.
Table 4. Plasma protein level of four study genes in 64 study subjects as a function of blood arsenic exposure, Lanyang Basin, Taiwan.a
Arsenic concentration in blood (µg/L) Correlation coefﬁcient for
Low Intermediate High individual measurements
Proteinb Total subjectsc 0.00–4.32 (number) 4.64–9.00 (number) 9.60–46.5 (number) ϒ p-Value
IL1b 53 0.65 ± 0.51 (18) 0.85 ± 0.53 (18) 0.74 ± 0.37 (17) 0.02 0.902
IL6 51 1.7 ± 1.8 (18) 2.4 ± 3.1 (20) 1.4 ± 0.9 (13) –0.19 0.190
CCL2/MCP1 64 498 ± 153 (21) 530 ± 183 (22) 611 ± 254 (21) 0.24 0.060
CXCL1/GRO1 32 42.2 ± 19.4 (12) 43.8 ± 18.4 (11) 47.9 ± 30.4 (9) –0.05 0.766
aProtein levels in plasma (pg/mL) are shown as mean ± SD. bInformation from the UniGene database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene). cSubjects with plasma
protein level below detection limit by ELISA assay were treated as having missing data.exposure groups. Several studies employ-
ing cell lines have defined the three
mitogen-activated protein (MAP) kinases,
including extracellular signal-regulated
kinase, stress-activated c-Jun N-terminal
kinase, and p38/CSBP (CSAID-binding
protein) protein kinase, that are involved in
the response to lethal levels of arsenite
(Cavigelli et al. 1996; Dong 2002; Liu et
al. 1996; Ludwig et al. 1998; Theodosiou
and Ashworth 2002). In this study, no
enhanced activation of MAP kinase path-
ways was observed in association with
arsenic exposure. Relatively low levels of
arsenic may have different modes of action,
as proposed by Barchowsky (Barchowsky et
al. 1999). MAP kinase pathways may not
be activated in the study subjects with rela-
tively low-level arsenic exposure, such as
those derived from drinking water. In con-
trast, the transcription factor SPI1 (spleen
focus forming virus proviral integration
oncogene), which is essential for the devel-
opment of hematopoietic system (DeKoter
and Singh 2000), is significantly upregu-
lated in lymphocytes from study subjects
with high levels of blood arsenic.
Deregulation in transcription levels can
also be found for genes involved in cell
cycle control and DNA replication/repair
processes, including induction of menage a
trois 1 (MNAT1), polymerase delta 2
(POLD2), and excision repair cross-
complementing rodent repair deficiency,
complementation group 1 (ERCC1) gene
expression, and reduction of cyclin C
(CCNC) and polymerase beta (POLB) gene
expression in intermediate- or high-level
arsenic groups compared with the low-level
arsenic groups. In contrast to the marked
induction of DNA damage-related proteins
noted in previous studies of the cell culture
system (Chen et al. 2001; Lu et al. 2001;
Yih et al. 2002), we did not observe sub-
stantial changes of DNA damage–inducible
transcripts gene expression associated with
arsenic exposure in these study subjects.
Perhaps the increased expression of genes
regulating DNA damage response is associ-
ated mainly with overt carcinogenic events.
In the present study, evidence for DNA-
damaging activity in lymphocytes from
arsenic-exposed study subjects was not sup-
ported. However, results of this study
showed that arsenic exposure induced
expression of cellular defense proteins, such
as heme oxygenase 1 (HMOX1) and glu-
tathione peroxidase 4 (GPX4). In many
mammalian systems of cell culture, eleva-
tion of HMOX1 is a hallmark of increased
oxidative stress induced by xenobiotic chal-
lenge, including arsenical compounds
(Elbirt and Bonkovsky 1999). GPX4 is a
component of the glutathione redox system
that protects cells against oxidative damage
induced by arsenic (Chouchane and Snow
2001; Lee and Ho 1994). Oxidative stress
has been proposed as an important mecha-
nism underlying arsenic-induced tissue
damage that leads to cell death or gene
expression changes (Bernstam and Nriagu
2000; Li et al. 2002; Nakagawa et al. 2002;
Snow 1992). In our previous study,
enhanced plasma oxidative stress levels
associated with arsenic exposure were also
observed for these study subjects (Wu et al.
2001). Among the genes of the MMPs
family spotted on our array, MMP1,
MMP12 (macrophage elastase), MMP14,
and MMP-19 had enhanced expression in
subjects from the high-level arsenic expo-
sure group. It has long been known that
increased MMP activity is important in
atheroma formation (Bendeck 2002). In
addition, increased production of MMPs
in activated leukocytes has unfavorable
effects for plaque stabilization (Libby 2002;
Schonbeck et al. 1997). In arseniasis-
endemic area in Taiwan, we observed an
increased risk of cerebrovascular disease
after long-term arsenic exposure to drink-
ing well water (Chen et al. 1996; Chiou et
al. 1997; Wang et al. 2002). In addition to
formation of atheroma, arsenic-induced
MMP activity leading to plaque rupture
and hemorrhage might play a role in cases
of advanced atherosclerosis observed in the
study area.
Many inflammatory molecules includ-
ing CCL2/MCP1 are regulated by nuclear
factor kappa-B (NF-κB), which is medi-
ated by oxidative stress (Kokura et al.
2002; Libermann and Baltimore 1990;
Shin et al. 2002). Arsenite has been shown
to induce oxygen free radicals and thereby
increase NF-κB activity in cell culture
studies (Barchowsky et al. 1996; Roussel
and Barchowsky 2000). Enhanced plasma
oxidative stress level associated with
arsenic exposure was also observed for the
present study subjects (Wu et al. 2001).
Arsenic exposure may contribute to ather-
osclerosis through induction of oxidative
stress and redox-sensitive inflammatory
gene expression in the vasculature of
exposed humans. A promoter analysis for
NF-κB binding sites on those upregulated
genes identified in this study may provide
implicative information on gene regulation
by arsenic exposure. Arsenic may alter
gene expression as well by inﬂuencing pro-
moter activity such as DNA methylation
status or sequence variants. Long-term
arsenic exposure in experimental animals
alters DNA methylation status (Zhao et al.
1997). Whether arsenic exposure causes
gene expression induction by a mechanism
of demethylation or sequence variants in
promoter region of all the affected genes in
these study subjects needs additional
experimental study. 
Several issues need to be addressed.
First, the cDNA microarray chip we used
in this study was designed to include
known genes of potential significance in
arsenic toxicity; however, only a defined
subset of genes was spotted in the cDNA
chip because of difﬁculty for clone mainte-
nance. It is possible that other gene prod-
ucts also play a role in arsenic-induced
atherosclerosis. Second, the decision to
pool the total cellular RNA from blood
lymphocytes of eight individuals into one
group was made to guarantee sufficient
mRNA for gene expression profiling as an
initial experiment. Because the extent of
variability among individuals within one
group was not available in this study,
reproducibility of comparison between
groups for RNA levels may be questioned.
However, because the 24 individuals were
grouped into various levels of the arsenic
dose group with similar age, male/female
ratio, and smoker percentage among
groups, comparability of the expression
profiles obtained as such should be
enhanced. This matching strategy should
increase the reliability of the microarray
Toxicogenomics | Wu et al.
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Table 5. Linear regression analyses on the logarithmic plasma CCL2/MCP1 protein levels for 64 arsenic-
exposed residents, Lanyang Basin, Taiwan.a
Variable Coefﬁcient (× 100) SEb (× 100) p-Valuec
Univariate analysis model
Age (1-year increment) 0.37 0.27 0.172
Gender (male vs female) 2.51 4.14 0.547
Blood arsenic (1-µg/L increment)  0.39 0.20 0.055
Body mass index, kg/m2 (1 unit increment) –0.86 0.53 0.112
Current smoker (yes vs no) 4.27 4.37 0.332
Serum cholesterol (one mmol/L increment) 0.03 0.06 0.666
Serum triglyceride (one mmol/L increment) 0.02 0.02 0.357
Multivariate analysis model
Age (1-year increment) 0.33 0.26 0.211
Gender (male vs female) 2.97 4.10 0.472
Blood arsenic (1-µg/L increment)  0.41 0.20 0.048
aPlasma CCL2/MCP1 protein level (pg/mL) in logarithm scale was detected by ELISA assay. bSE: standard error of the
coefﬁcient. cProbability derived from a Wald’s chi-square test for the hypothesis that coefﬁcient = 0.data. In addition, an alternate measure of
gene expression, ELISA assay, was used to
confirm the initial gene array analysis
genes, which adds substantially to the
reproducibility of this study. Third, as only
one chip was spotted for each dose level in
this study and the variability across chips
was thus not obtainable, a standard curve
using serial-diluted GAPDH clones was
generated to control the variation between
hybridization experiments, including vari-
ability from chip to chip. Furthermore, the
variance in expression of the housekeeping
genes was used to measure the signiﬁcance
of gene expression changes for study genes.
As the variability in the expression of
housekeeping genes probably overestimated
the experimental variability in measuring
differential expression, the resulting com-
parison under study should have been
underestimated. Finally, the number of
study subjects may not be large enough for
most of the genes under study to draw a
definitive conclusion on the association
between expression level and arsenic expo-
sure gradient. A larger sample size will be
needed, especially for studies using diverse
human population and gene markers of
great experimental variability, to evaluate
the effect of environmental factors on the
gene expression proﬁle.
In conclusion, this exploratory study
demonstrates the potential of cDNA
microarray as a method to identify candi-
date genes associated with arsenic exposure,
an atherogenic stimulus, and provides
novel investigational targets including
genes involved in inflammation and
immune response. Although PBL is not
representative of all inflammatory cells in
atherosclerotic lesion areas, the result of a
dose-dependent elevation of plasma
CCL2/MCP1 protein levels in the study
subjects may yield insight into the response
to atherogenic stimulus after long-term
arsenic exposure. Further research that
extends the sample size of this study as well
as exploration of gene expression proﬁle of
other inflammatory cytokines and growth
factors in arsenic-exposed population are
needed to define the dose–response rela-
tionship between the exposure and inﬂam-
matory mediators at the population level.
Multidisciplinary studies such as molecular
epidemiologic investigations are also
needed to elucidate the role of arsenic-
associated inflammation in the induction
of atherosclerosis.
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